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Abstract 
Polymeric particles are a versatile class of local or systemic drug delivery systems, used to improve drugs 
pharmacokinetics and pharmacodynamics along with patient compliance. Herein, we report a rapid, 
scalable, and optimized method to encapsulate ciprofloxacin (CPx), a poor water soluble antimicrobial 
agent, in gelatin microparticles by single step processing via spray-drying of an aqueous solution. The 
developed particles show mainly a wrinkle morphology with a unimodal distribution, with mean diameters 
ranging between 2 and 4 μm, depending on the processing conditions. The encapsulation of 1, 2 and 5 
wt% CPx narrows the size distribution (1-3 μm). In vitro release experiments showed that up to 80% of 
encapsulated drug is released during the first 6 h, and the release kinetics was best fitted with the 
Korsmeyer-Peppas model, explained by the superimposition of drug diffusion and polymer chain 
relaxation. The minimal inhibitory concentrations against S. aureus and E. coli, obtained from pure and 
encapsulated ciprofloxacin, demonstrated that the spray-drying process does not inhibit the drug's 
bioactivity or the process feasibility. Thus, spray-drying of protein-drug particle systems is an 
advantageous method to produce microparticles with potential to lung delivery systems. 
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Polymeric particles are a versatile class of local or systemic drug delivery systems, used 
to improve drugs pharmacokinetics and pharmacodynamics along with patient 
compliance. Herein, we report a rapid, scalable, and optimized method to encapsulate 
ciprofloxacin (CPx), a poor water soluble antimicrobial agent, in gelatin microparticles 
by single step processing via spray-drying of an aqueous solution. The developed 
particles show mainly a wrinkle morphology with a unimodal distribution, with mean 
diameters ranging between 2 and 4 𝜇𝑚, depending on the processing conditions. The 
encapsulation of 1, 2 and 5 wt% CPx narrows the size distribution (1-3 𝜇m). In vitro 
release experiments showed that up to 80% of encapsulated drug is released during 
the first 6 hours, and the release kinetics was best fitted with the Korsmeyer-Peppas 
model, explained by the superimposition of drug diffusion and polymer chain 
relaxation. The minimal inhibitory concentrations against S. aureus and E. coli, 
obtained from pure and encapsulated ciprofloxacin, demonstrated that the spray-
drying process does not inhibit the drug`s bioactivity or the process feasibility. Thus, 
spray-drying of protein-drug particle systems is an advantageous method to produce 























Particulate systems are a class of drug delivery systems of great clinical and research 
interest for both local and systemic delivery, which are designed to improve drug 
bioavailability, stabilization, pharmacokinetics and selectivity, while avoiding toxicity 
issues raised by added excipients, continuous administration or tissue accumulation [1, 
2]. Those systems are particularly appealing for pharmaceutical industry due to their 
versatility, enabling topical, pulmonary, nasal or parenteral administration [2, 3] in 
creams [4], hydrogels [5], dry powders and aerosols [6, 7] or injectable formulations 
[8]. 
Drug loaded polymeric particles fabrication often rely on drying of a droplet containing 
the formulated mixtures from dissolved, dispersed or emulsified substances [9, 10]. 
Most relevant techniques include spray-drying [7, 11], spray freeze drying [12], and 
electrospray [13], among others. Spray-drying is a well-established technology in the 
pharmaceutical and food industry, for microencapsulation [14, 15]. This a continuous, 
single step, cost-effective and scalable technique that allows for the tuning of the final 
particles properties [9, 16] and for the processing of heat sensitive molecules 
(proteins, peptides or drugs) which, in turn, enhance the bioactivity of the final 
formulations [17, 18]. This is due to the fast solvent evaporation of droplets with high 
surface area-to-volume ratio [18]. Furthermore, the encapsulation of hydrophobic 
molecules is also possible by the atomization of emulsified feed solution, introducing 
then an extra processing step [19, 20]. 
Natural polymers are often a smart choice when developing medical devices mainly 
due to their biocompatibility and biodegradability. Gelatin is a natural biopolymer, 
















since it is considered as a GRAS (generally recognized as safe) material by the FDA [21]. 
Despite its animal source, toxicity and antigenicity issues are minimal due to acid/alkali 
hydrolysis of collagen during processing [21, 22]. Other attractive features of gelatin 
for drug delivery systems include the available functional groups for the coupling of 
ligands, targeting or the stabilization by crosslinking, increasing circulation times [21]. 
In this work, an alternative source of gelatin – fish gelatin – was chosen, which, 
considering the targeted application, would reduce the concerns about prion 
transmission related with animal sources of gelatin [23]. 
Ciprofloxacin (CPx) is a broad-spectrum fluoroquinolone antibacterial agent indicated 
for the treatment of acute cystitis, chronic prostatitis, urinary and lower respiratory 
tract infections, acute sinusitis, skin infections, bone and joint infections, among others 
[24]. It is also administered to treat opportunistic Pseudomonas aeruginosa in cystic 
fibrosis patients [24]. CPx acts by inhibition of bacterial DNA gyrase and topoisomerase 
IV that disrupts bacterial DNA replication [25]. Side effects associated with CPx use, 
including gastrointestinal, cardiovascular and allergic reactions and nervous system 
complaints [26], along with its poor water solubility and bioavailability [24, 27] 
motivates the development of effective encapsulations systems.  
This work reports the development and optimization of gelatin microparticles for CPx 
encapsulation using an orthogonal design by a single-step procedure using spray-
drying. The developed microparticles were characterized by SEM, FTIR and thermal 
analysis and the in vitro release profile was fitted to the mathematical release models. 
The crosslinking effect (glutaraldehyde) on the microparticle diameter was also 
















bactericidal concentrations against susceptible strains of E. coli (Gram-negative) and S. 
















2. Material and methods 
2.1. Materials 
Gelatin (gel) from cold water fish skin, glutaraldehyde solution (GA; 50 wt.%) and 
ciprofloxacin (CPx; ≥ 98.0%) were supplied by Sigma-Aldrich. All reagents and 
chemicals used were of analytical grade.  
 
2.2. Polymer particle processing  
Gel solutions were prepared in double distilled water (ddH2O) at different 
concentrations (0.5, 1 and 2 % w/v) under magnetic stirring at 50 ºC and cooled to 
room temperature (25ºC) before use.  
For gel-CPx formulations, a stock solution of CPx in 0.1N HCl was prepared separately 
and added to a gel solution (0.5 % w/v) for a final CPx concentration of 1, 2 and 5 wt%.  
Spray-drying was performed using a home-made system (figure 1). The experimental 
parameters range for gelatin concentration, feed rate and inlet temperature are 
detailed in Table 1.  
 
2.3. Experimental design 
The influence of the processing parameters on gel microparticles produced by spray-
drying was evaluated by an orthogonal design table 𝐿9, using Orthogonal Design 
Assistant II software (Sharetop Software Studio). Each orthogonal table has its own 
mark denoted as (1): 
𝐿𝑛(𝑡)
𝑐 (1) 
where 𝐿 represents the orthogonal table of 𝑛 experiments, 𝑡 is the number of levels of 
















defined factors of polymer concentration (A), feed rate (B) and inlet temperature (C), 
their levels and the experimental set up for the nine experimental conditions (A-I) are 
describe in Table 1. 
The selection of optimal conditions was based on the orthogonal parameters K and R, 










where 𝐾 and 𝑅 represents the mean and range values, respectively, for a factor 𝐹 at 
the level 𝑙 [28, 29]. The impact of the three factors (gel concentration, feed rate and 
inlet temperature) on the average particle diameter was evaluated by investigating the 
influence of different levels of each factor [28]. The determination of the factors order 
was achieved by calculating the range (𝑅) for each factor upon evaluation indexes (𝐾𝑖). 
 
2.4. Rheology 
The rheological behavior of gel solutions with different protein concentrations (0.5, 1 
and 2 % w/v) were evaluated using a parallel plate (∅ = 20 𝑚𝑚) geometry rheometer 
(MCR 301, Anton Paar) with a 0.3 mm gap to ensure adequate filling of the samples 
over the testing disk. Viscosity was measured as a function of shear rate within the 


















2.5. Polymer particles crosslinking 
Dry particles were crosslinked using 20 mL of a glutaraldehyde solution (50 % in H2O, 
Sigma-Aldrich) in the vapor phase, in a vacuum chamber (VACUO-TEMP, JP Selecta, 
Spain), at room temperature, and under low pressure for 72 h. 
 
2.6. Particles characterization 
Particles were coated with a thin gold layer using a sputter coater (Smart Coater, JEOL) 
and their morphology was analyzed using a scanning electron microscope (JCM-
6000PLUS Neoscope, JEOL), with an accelerating voltage of 10 kV. Particles average 
diameter and its distribution was calculated over 300 particles in SEM images (1,000 x 
magnification) using the Image J software [30]. Particles dispersity was quantitatively 






where 𝜎 represents the standard deviation of the mean particle size (𝜇) [31]. 
Infrared (FTIR) measurements were performed in a Shimadzu IRAffinity-1S apparatus 
in ATR mode from 4000 to 600 cm-1, at room temperature. FTIR spectra were collected 
after 32 scans with a resolution of 2 cm-1. Differential scanning calorimetry (DSC) 
measurements were performed with a TA Q100 apparatus (TAinstruments), between 
30 and 200 ºC at a heating rate of 10 ºC.min-1, under a nitrogen purge. 
Thermogravimetrical analysis (TGA) was conducted in a Q500 apparatus 


















2.7. Determination of CPx loading 
The CPx loading was determined by dissolving the dry gel-CPx microparticles in 0.1 M 
HCl, in ultrasonic bath for 6 h followed by mechanical stirring at 37 ºC. After 72 h, the 
suspensions were centrifuged (10,000 rpm, 10 min) to remove polymeric debris and 
the CPx was measured in the supernatants using a spectrophotometer (Shimadzu 
UV1800), using crosslinked drug-free gel particles as blank controls. The drug loading 
was calculated per equation 5, using a calibration curve of CPx in 0.1 M HCl (equation 
6) at 𝑂𝐷 = 277 𝑛𝑚, where 𝑥 is the drug concentration (𝜇𝑔/𝑚𝐿) and 𝑅2 is the 
coefficient of determination. 
 
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =




𝑂𝐷277𝑛𝑚 = 0.1245𝑥 + 0.004768 (𝑅
2 = 0.999) (6) 
2.8. In vitro CPx release 
Gel-CPx suspensions (10 mg mL-1; 5 mL) were transferred to a tubular dialysis 
membrane with a MWCO of 1 kDa (Cellu.Sep H1, Fisher Biotec). The membranes were 
then immersed in 200 mL of PBS (pH 7.4), under smooth magnetic stirrer (100 rpm) at 
37 ºC. At predetermined time intervals, 2 mL of the release medium was withdrawn 
and replaced with fresh PBS. The release medium was measured at 𝑂𝐷 = 270 𝑛𝑚 
using a UV-VIS spectrophotometer (Shimadzu UV1800) and the CPx amount was 
















(𝜇𝑔/𝑚𝐿) and 𝑅2 is the coefficient of determination. Results were expressed as % 
cumulative release relative to the initial weight of CPx loaded in the particles. Analysis 
was performed in triplicates and results were averaged.  
𝑂𝐷270𝑛𝑚 = 0.09847𝑥 + 0.001677 (𝑅
2 = 0.998) (7) 
The experimental results were fitted to the first order (8), Higuchi (9) and Korsmeyer-
Peppas (10) models to further evaluate the release kinetics.  
log 𝐶 = 𝑙𝑜𝑔𝐶0 − 𝐾𝑡/2.303 (8) 
𝑀𝑡
𝑀∞
= 𝐾√𝑡 (9) 
𝑀𝑡
𝑀∞
= 𝐾𝑡𝑛 (10) 
where 𝐶 and 𝐶0 are, respectively, the cumulative and initial amounts of drug, 𝑀𝑡/𝑀∞ 
is a fraction of drug released at time 𝑡, 𝐾 is the rate constant, and 𝑛 is the exponent 
that characterizes the release mechanism [32, 33]. 
 
2.9. Determination of the antibacterial activity of Gel-CPx particles 
The susceptibility of Staphylococcus aureus (ATCC29213) and Escherichia coli 
(NCTC8196) to the gel-CPx (5 wt%) microparticles was evaluated by broth 
microdilution assay as previously described, with slight modifications [34]. Briefly, 
















tryptone 10 gL-1, yeast extract 5 g L-1, NaCl 10 g L-1, agar 15 g L-1, pH 7.4) plates and 
incubated overnight at 37 ºC. Overnight cultures of S. aureus and E. coli were prepared 
from single colonies in Brain-heart infusion (BHI; 37 g L-1, pH 7.4) or LB broths, 
respectively, at 37 ºC in an orbital shaker (160 rpm).  
Dry formulations of gel (uncross- and crosslinked) and gel-CPx (5 wt%) microparticles 
(crosslinked) were sterilized prior to incubation by UV exposure for 25 min. To ensure 
sterility of UV-irradiated samples, 100 µL of stock solutions was plated in LB agar and 
blood-agar media and monitored for bacterial growth. CPx concentration in 
formulations was calculated per the percentage of drug entrapment. Controls of pure 
CPx were prepared from a stock solution (30 µg mL-1) in PBS (pH 7.4) and sterilized by 
filtration. All experimental formulations were then 2-fold serially diluted in 100 𝜇l of 
culture medium to reach the tested concentrations. Each well was then inoculated 
with 100 𝜇L of bacterial suspension containing 
1𝑥106 𝐶𝐹𝑈 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠) 𝑚𝐿−1.  
Bacterial cultures were then incubated for 18-20 h at 37 ºC and the minimum 
inhibitory concentration (MIC) was determined as the lowest concentration with clear 
wells, using a microplate reader (SpectraMax Plus 384, Molecular devices, USA) at 
OD600 nm. Minimum bactericidal concentration (MBC) was determined by plating 10 µL 
of each well with growth inhibition (clear wells) on LB agar medium. Following 
incubation for 24 h at 37 ºC, MBC was determined as the lowest concentration where 



















2.10. Data analysis 
Quantitative data are presented as mean ± standard deviation (SD). Significant 
differences were determined by one-way ANOVA analysis with Tukey`s HSD post hoc 
test using GraphPad Prism Software (v 6.01). Statistical differences were considered 
when 𝑝 < 0.05. 
 
3. Results and discussion 
3.1. Optimization of gelatin microparticles 
The average particle diameter was the measured response of the orthogonal design to 
produce gel microparticles by spray-drying technique, in a single step, avoiding 
intermediate steps, such as emulsification. Results of average particle diameter, 
coefficient of variation and orthogonal indexes are presented in table 2, for the 
experimental runs from A to I (table 1). The larger the 𝑅 parameter, the more 
influence of the factor on the process, reflecting either valuable or detrimental effects 
[28, 29, 35, 36]. For the processing of gel microparticles by spray-drying, gelatin 
concentration is the most important factor followed by the feed rate and the inlet 
temperature (𝐴 > 𝐵 > 𝐶). Figure 2 depicts the influence of tested factors and levels 
on the average particle diameter and coefficient of variance. Despite the narrow 
diameter range of the experimental runs (between 2.62 ± 0.78 and 3.65 ± 1.17 𝜇𝑚), it 
can be pointed out a concentration-dependent increase in particle diameter (figure 2a) 
that can be mainly addressed to the increased viscosity of the feed solution (figure 2b). 
















lower (0.5 and 1 % (w/v)) and the highest concentration (2 % (w/v)); the first ones 
showed a typical Newtonian behavior, whereas the 2 % (w/v) solution behave as a 
shear thinning fluid. For instance, for lower shear rates the difference in the viscosity is 
up to 7 times for the 2 % (w/v) solutions (figure 2b – inset). The relationship between 
feed solution concentration and particle size has been reported by Elversson et al. for 
lactose powders, where the increase in concentration lead to larger particles, although 
the effect was not linear [37]. 
The influence of the tested factors and levels on the particles dispersity, quantitatively 
evaluated by the 𝐶𝑉, were almost negligible, and similar values were found for all 
experimental runs, and all below 0.5 (table 2). The water content in dry formulations is 
of outmost importance for the formulation preservation and for the improvement of 
shelf-life [38]. The overall variation in the moisture content for the orthogonal 
experiments (figure S1) was less than 2 % and, therefore, it is not influenced by the 
studied levels.  
The selection of the optimal combination is determined by the smallest index and, for 
this work consisted of a feed concentration of 0.5% (w/v), using a feed rate of 308 ml 
h-1 at 115ºC. However, the optimal feed rate had to be adjusted for the subsequent 
experiments to the following level (177 ml h-1) due to the moisture introduced in the 
sample collector, that dissolved the formed particles and leading to a non-continuous 
processing. 
The samples collected after spray-drying presented a mixture of wrinkled (mostly) and 
a few smooth spherical particles, as depicted in figure 3, following a unimodal 
distribution (figure 4), in accordance with the lower 𝐶𝑉 values (table 2). Irregular 
















associated with high Peclet numbers, which relates convection and diffusion 
phenomena and is influenced by the solvent evaporation rate [16]. Nevertheless, 
wrinkle-shaped albumin particles showed better performance in aerosolization studies 
due to its lower contact area that decreases the powder cohesiveness [39]. 
 
3.2. Characterization of Gel-CPx particles 
Ciprofloxacin (CPx)-loaded gelatin microparticles were produced by single-step spray-
drying following the best experimental conditions determined in section 3.1. The gel 
crosslinking was performed in the vapor phase to improve particle stability, while 
diminishing possible cytotoxic effects associated with the crosslinking agent (GA) [19, 
40]. Both uncross and crosslinked particles obtained by spray-drying presented a 
wrinkled surface morphology (figure 5 a – d) like the ones observed in the orthogonal 
experiments (figure 3). Overall, the presence of CPx induced a narrower particle size 
distribution (figure 5 e - f), presenting a higher impact on the particle size rather than 
the crosslinking itself. Statistical differences were found between uncross and 
crosslinked samples only for 0 and 1 % wt CPx. It was reported that the use of GA as a 
crosslinking agent for gelatin, did not changed significantly the sample fiber diameter 
[41, 42]. Furthermore, the moisture content for the CPx-loaded formulations (figure 
S2) was comparable to the drug free ones. 
Average diameters for CPx-loaded particles ranged from 2.73 ± 0.84 𝜇𝑚 to 
2.93 ± 0.86 𝜇𝑚 for the uncrosslinked samples, and from 2.61 ± 0.70 𝜇𝑚 to 
2.79 ± 0.80 𝜇𝑚 for the crosslinked ones. The crosslinking also lowered coefficient of 
















Considering the optimal particle size for the lung administration of small molecules, 
the obtained particle size shows potential to target the alveolar region. It was reported 
that particles in the narrow window of 1 – 5 m, behave more like gas molecules and 
follow airflow all the way to the alveoli by a number of mechanisms, including 
diffusion, sedimentation, and electrostatic effects [43]. Particles in the range size of 1 – 
3 𝜇m are in peak of alveolar deposition [6, 44-46]. 
CPx loading was carried out according to the procedure detailed in the experimental 
section, and the efficiency achieved was above 94 % (Table 3). Spray-drying of an 
aqueous solution of gelatin proved to be suitable to incorporate CPx, and thus, 
avoiding the incorporation of any other organic solvents in the mixture, being also 
environmentally friendly. 
The infrared spectrum of pure CPx, gel and gel-CPx (5 %wt.) particles is depicted in 
figure 6. The protein characteristic absorption bands were observed both in gel and 
gel-CPx particles at approximately 1650 cm-1 (amide I), 1540 cm-1 (amide II) and 1240 
cm-1 (amide III), corresponding to the stretching vibrations of C=O bond, to the 
coupling of bending of N-H bond and stretching of C-N bonds, and to the stretching of 
C-N bonds plus the in-phase bending of N-H bonds, respectively [47, 48]. It was 
possible to observe the CPx absorption band at 1284 cm-1, assigned to the C-N 
stretching [49], in the microparticles FTIR spectra, confirming its presence in the drug-
loaded particles. Moreover, it can be observed that the particle processing does not 
suppress totally any absorption modes nor new vibrational modes seem to appear 
suggesting the absence of covalent bonds between gelatin and the drug. 
 
















DSC curves of microparticles and free CPx are reported in figure 7a. CPx showed to be 
stable within the range of the processing temperatures. DSC data recorded for the 
pristine gelatin and gelatin loaded with CPx, showed similar trends, suggesting that the 
spray dry process does not influence the polymer thermal properties. A broad 
endothermic peak at lower temperatures, between 30 – 120 ºC was attribute to the 
volatilization of absorbed and unbonded water present in the gelatin particles (figure 
7a). The presence of water molecules in the particles is probably due to the storage 
and handling of the sample, at room conditions. Gelatin is a hygroscopic protein, and 
can trap up to 12 wt% of water from moisture [50, 51]. The characteristic helix-coil 
transformation of gelatin was detected at ~190 ºC [52]. Moreover, the enthalpy of the 
helix -coil decrease from 15.9 J g-1 for the pristine gelatin samples, down to 1.9 J g-1 for 
the sample loaded with 5 wt% of drug. These results suggest that the presence of CPx 
alters the formation of the characteristic helical structure, probably disrupting the 
hydrogen bonds between the polymer chains, by creating new hydrogen interactions 
between hydroxyl groups and amides present in both, drug and in the polymer chains 
[53]. Peña et al. reported that the incorporation of tannin in gelatin films, led to a 
decrease of the enthalpy of the helix-coil structure, from 15 J.g-1, calculated for pristine 
gelatin films, down to 3 J g-1, for a sample with 30 wt% tannin [53]. This behavior was 
attributed to the tannin ability to modify the hydrogen bonding between the protein 
chains, and creation of new hydrogen interactions between the tannin hydroxyl groups 
and gelatin polar groups. 
Thermogravimetric analysis was performed to the prepared unloaded and loaded 
gelatin particles. Two different weight loss steps can be distinguished in figure 7b. The 
















absorbed during sample storage and handling [50, 53]. The second degradation step, 
that occurred between 250 – 400 ºC, was attributed to the protein helix structure 
chain breakage, and peptide bonds rupture [53, 54]. The residual weight of the protein 
(≈35 wt%) agrees with the values reported in literature [54, 55]. 
 
3.4. In vitro release studies 
The cumulative in-vitro release of CPx carried out at physiological pH is depicted on 
figure 8a. All tested formulations presented a similar release profile where the 
complete release was achieved within 24 hours. The release profiles of the gel-CPx 
microparticles with different amounts of drug showed a burst release within the first 6 
hours, followed by a slower release rate (figure 8a).  
Gelatin particles can be seen as a polymeric network swollen with solvent, where the 
water fills the space between the strands of the polymer chains [56, 57], and act as 
permeation channels. When the drug loaded particles are immersed in the release 
media, the polymer is capable to uptake the water based media, followed by 
relaxation of the macromolecular chains and volume expansion, and the CPx drug can 
diffuse to the external receptor medium from within the gelatin microparticle. The 
suggested mechanism for the CPx release is presented in figure 8b. 
The obtained release profiles of the gelatin microparticles were in between of some 
gelatin systems reported in literature obtained via emulsion and desolvation 
techniques. The developed system had a more sustained release over time than a 
paclitaxel-loaded system with 90 % release in 2 h [58], but a faster release compared 
















on drug-gelatin ratio, and amount of poly(methyl methacrylate) present in the oil 
phase, during the preparation of the emulsion [56].  
The release profile was further investigated, and the experimental data was modelled 
to the first order, Higuchi and Korsmeyer-Peppas (KP) models, and the kinetic 
parameters are presented in table 4. The best fittings were obtained for first-order and 
KP models with coefficients of determination higher than 0.98. 
Despite having similar profiles, the calculated release rate tends to increase with the 
increasing of drug loading in the system, an effect already reported [56]. According to 
KP model, a statistically significant increase in release rate was obtained between 1 
wt.% and 2 wt.% formulations, which could be due to the high distance that the drug 
must travel from the core of the polymeric particle to the release medium, and 
consequently decreasing the release rate. However, no significance was obtained 
between those formulations and the 5 wt.% ones, being more similar to the 2 wt.%, 
which indicates that for contents above 2 wt.% the release rate is not influenced by 
spatial effects. 
Berkland et al. [59] reported the effect of particle size (10 to 100 𝜇m) on drug release 
kinetics but such effect cannot be attributed to this gel-CPx system since the mean 
diameter differences are almost negligible (figure 5 - f). Thus, differences in 𝑘 values 
can be mainly addressed to geometrical factors, since particles having smaller drug 
loadings provide a larger path to the drug molecules to reach the release media (figure 
8b). 
Drug release from a polymeric system can be due to relaxation of the polymer chains 
over time, resulting in additive movement out of the polymer matrix; due to diffusion, 
















within the polymer, or degradation controlled, where part of the polymer dissolves in 
the release medium which causes the release of the drug present in that part of the 
polymer network [60, 61]. For the spray dried gelatin microparticles, drug release due 
to erosion of the polymer matrix is unlikely, as crosslinked gelatin does not dissolve 
under existent experimental conditions and its biodegradation starts at a time longer 
than that taken into consideration [50]. Thus, the mechanism of CPx release could be 
either diffusion or relaxation controlled, and can be elucidated by the value of the 
diffusion exponent (n) predicted by the KP model (equation 10). The value of n, 
summarized in table 4, suggests that a n value between 0.69 up to 0.75, and therefore, 
the release of CPx may be considered as an anomalous transport and indicate a 
superimposition of the two mechanisms - drug diffusion and polymer chain relaxation 
(0.43 < n < 0.85, for spherical systems) [32]. 
 
3.5. MIC and MBC determination for CPx-loaded particles 
The bioactivity of released ciprofloxacin was investigated by determining the minimal 
inhibitory and bactericidal concentrations against susceptible strains of E. coli (Gram-
negative) and S. aureus (Gram-positive). The dose-dependent curves of bacterial 
growth (figure 9) and MIC/MBC values (table 5) showed similar growth profiles for 
pure or encapsulated CPx for both bacteria. Unloaded gel particles (uncross- and 
crosslinked with GA) did not affect bacterial growth, mitigating any possible influence 
of GA in the MIC values. MIC and MBC values determined against S. aureus and E. coli 
were comparable for pure or encapsulated drug. Experimental MICs were consistent 
with those reported in literature for ciprofloxacin against non-resistant strains of S. 
















ciprofloxacin after processing by spray-drying and suggest that the process does not 




This work reports a facile and fast method of producing gelatin microparticles loaded 
with ciprofloxacin, a poorly water soluble antibacterial agent, with great potential for 
scale-up. Gelatin-ciprofloxacin particles with mean diameter between 2 and 3 𝜇𝑚 were 
developed by single step procedure, with loading efficiencies above 94% and an in 
vitro release profile over the first 6 hours. Loaded ciprofloxacin activity was 
demonstrated against S. aureus and E. coli, showing MIC and MBC values comparable 
to the pure CPx. 
Spray-drying of protein-drug particle systems could be an advantageous alternative to 
emulsions, providing higher production rates, and given their features might have 
potential to lung administration of drugs. 
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Figure 1 – Spray dry apparatus used in the production of the gelatin microparticles. 
 
Figure 2 – a) Relationship between the average particle diameter (black) and 
coefficient of variation (red) and the factors and levels of the orthogonal experimental 
design, and b) Viscosity of gelatin solutions (0.5, 1 and 2 % w/v) as a function of shear 
rate at 25ºC; inset: viscosity dependence on gelatin concentration at a shear rate of 10 
s-1. 
 
Figure 3 – Morphology of gelatin particles obtained at experimental processing 
conditions from A to I analyzed by SEM.  
 
Figure 4 – Particle (conditions A to I) diameter distribution obtained from, at least, 300 
particles/sample using ImageJ software. 
 
Figure 5 – Morphology of gelatin microparticles obtained by SEM analysis: (a) un-
crosslinked gel-CPx 0 % wt, (b) crosslinked gel-CPx 0 % wt., (c) un-crosslinked gel-CPx 5 
% wt., (d) crosslinked gel-CPx 5 % wt. Size distributions (e) and average diameter (f) for 
un-crosslinked (dash) and crosslinked (line) gel-CPx formulations (0, 1, 2 and 5 %wt). 
Inset: coefficient of variation (𝐶𝑉) for the formulations. * represents differences by 
comparison with each control (un-crosslinked) and § represents comparisons between 

















Figure 6 – Fourier transformed infrared spectra of pure ciprofloxacin (CPx) and gelatin 
particles with 0 and 5 wt% of CPx. 
 
Figure 7 – Thermal analysis of pure CPx and gel-CPx particles: (a) differential scanning 
calorimetry and (b) thermal degradation profile of recorded at 20 °C.min-1. 
 
Figure 8 – a) In vitro release of ciprofloxacin (CPx) from gel-CPx formulations with 
different loadings. Experiments were performed in triplicates in PBS buffer (pH 7.4) at 
37 ± 0.5 ℃; b) proposed release mechanism for CPx. 
 
Figure 9 – MIC measurements for pure ciprofloxacin (CPx) and gel-CPx formulations 
against S. aureus and E. coli. Unloaded gelatin particles uncross (gel-uncross) and 



























Table 1 – Factors (A, B and C), levels (1, 2 and 3) and experimental conditions of 
Orthogonal experimental design 𝐿9(3)
4 for producing gelatin microparticles by spray-
drying. 
 
Table 2 –Diameter and coefficient of variation (CV) of gelatin particles and orthogonal 
indexes calculated from particles diameter. 
 
Table 3 – Ciprofloxacin loading (%) in gelatin particles calculated by UV-VIS analysis. 
 
Table 4 – Kinetic parameters for first order, Higuchi and Korsmeyer-Peppas models 
determined from fitting of release experiments for the three formulations of gel-CPx 
particles. 
 
Table 5 – Comparison of MIC and MBC values for pure ciprofloxacin and gel-CPx 
formulations against S. aureus and E. coli using broth microdilution test. Results are 



















Levels A (% w/v) B (ml h-1) C (ºC) 
1 0.5 90 115 
2 1 177 130 
3 2 308 140 
Experiment Levels 
A 1 1 1 
B 1 2 2 
C 1 3 3 
D 2 2 1 
E 2 1 3 
F 2 3 2 
G 3 1 2 
H 3 2 3 



















Experimental runs Diameter ± SD (µm) CV 
A 2.63 ± 0.71 0.27 
B 2.76 ± 0.75 0.27 
C 2.62 ± 0.78 0.30 
D 2.80 ± 1.09 0.39 
E 3.14 ± 1.02 0.32 
F 2.83 ± 1.05 0.37 
G 3.65 ± 1.17 0.32 
H 3.57 ± 1.33 0.37 
I 3.25 ± 1.32 0.40 







𝐾1 2.668 3.139 2.894 
𝐾2 2.925 3.045 3.081 
𝐾3 3.492 2.901 3.110 
Range 𝑅 0.824 0.237 0.217 
Order 𝐴 > 𝐵 > 𝐶 



















Samples Drug loading (%) Efficiency (%) 
Gel-CPx 1 wt.% 1.0±0.03 100 
Gel-CPx 2 wt.% 1.95±0.37 97.5 





















First Order Higuchi Korsmeyer-Peppasa 
k R2 kH R









































 calculation of kinetic parameters considered values below 60% release, following model assumptions 
[32] 
* 





















 MIC (𝜇𝑔/𝑚𝑙) MBC (𝜇𝑔/𝑚𝑙) 
 S. aureus E. coli S. aureus E. coli 
Pure CPx 0.25 0.008 0.667±0.236 0.011±0.004 




















 A single step method to produce gelatin-ciprofloxacin microparticles is 
presented. 
 Spray-drying led to microparticles with suitable diameters for lung 
administration. 
 80 % of the encapsulated drug is released over 6 h, with MIC like the free drug. 
 This scalable method shows potential for dry systems in pharmaceutical 
industry. 
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